Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
We stand for long-term partnerships and excellent service. Innovation and technological leadership are as important to us as quality and operational excellence. Our passionate and dedicated employees, along with our unique corporate culture are the foundation of our success.
A big thank you from the leadership team
Health, Safety, Environment (HSE) at Bachem - by Sandra Thöni
Innovation for peptide and oligonucleotide manufacturing - a few examples
Corporate Social Responsibility at Bachem - by Franz Saladin
Peptide-based In Vitro Diagnostics
Generic Active Pharmaceutical Ingredients - Liraglutide and other GLP-1 analogues
Meet Gilles Parmentier- Head of Global Research Chemicals & Specialties
2022 Annual Results - A word with… Thomas Meier, CEO of Bachem
Bachem Oligonucleotide facility tour - Trailer
Semaglutide! What is it, and how does it work?
Peptides - CMC development for NCE projects quickly explained
Corporate Executive Committee looks back at 2022
Regulatory Affairs Services - Partnering for Success
Lyophilization of Peptides and Oligonucleotides
Bachem in Generics - Leading by Experience
Smart Factory at Bachem: Automating and Digitalizing SPPS
Continuous chromatography | sustainable optimization of yield & quality
The successful journey of large scale oligonucleotide manufacturing
Sustainable Propofol manufacturing in Switzerland
Risk assessment for a nitrosamine contamination of peptide APIs manufactured by SPPS
AMW | Customer testimonial | Why choose Bachem?
Oligonucleotides at Bachem - Innovation that transforms lives
Novel and best approaches in MS characterization of highly modified synthetic RNA?
Industry 4.0 for manufacturing of oligos and peptides
CMC development of peptides - A case study
Bachem Corporate Management - Do They Still Recall Their First Day?
2021 Full Year Results - Leadership’s perspectives & highlights
Expanding into Oligos - Interview
Oligonucleotides - Innovation that transforms lives
Do it Right, by not Doing it Yourself – the Value of a Good CDMO Partner